Lyell Immunopharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $359.3M
- Price
- $15.40
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.69%
- Volume
- 270.6K
Quote data as of 7:03 AM ET
About
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding23.3M
Computed float6.6M
Float sourceUnknown
Cash runway (months)19.7
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001806952
Websitehttps://www.lyell.com
AI Summary
AI-generated27d agostandardbullishclinical trialLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Lyell Immunopharma presented updated safety data for ronde-cel in 108 patients with relapsed or refractory large B-cell lymphoma at the EHA 2026 Congress.
The data showed no Grade 3 or higher Cytokine Release Syndrome (CRS) events and low rates of Grade 3 or higher Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), supporting the potential for outpatient administration.
Translational insights highlighted the biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells via CD62L+ enrichment and dual-targeting of CD19/CD20.
The company expects updated data from the pivotal PiNACLE trial in the second half of 2026, with a BLA submission targeted for the second half of 2027.